Detalles de la búsqueda
1.
Effect of Bimekizumab on Patient-Reported Disease Impact in Patients with Psoriatic Arthritis: 1-Year Results from Two Phase 3 Studies.
Rheumatology (Oxford);
2024 May 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38754125
2.
Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data.
Rheumatol Ther;
11(3): 487-499, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38696034
3.
Remission and low disease activity are associated with lower healthcare costs: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
Ann Rheum Dis;
2024 May 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38754981
4.
BASDAI versus ASDAS in evaluating axial involvement in patients with psoriatic arthritis: a pooled analysis of two phase 3 studies.
Rheumatol Adv Pract;
8(2): rkae058, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38765190
5.
Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses.
Arthritis Rheumatol;
2024 May 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38770592
6.
Anti-KIF20B autoantibodies are associated with cranial neuropathy in systemic lupus erythematosus.
Lupus Sci Med;
11(1)2024 Apr 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38599670
7.
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis.
Rheumatol Ther;
11(2): 425-441, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38386178
8.
Use of Apremilast to Achieve Psoriatic Arthritis Treatment Goals and Satisfaction at 1 Year in the Canadian Real-World APPRAISE Study.
Rheumatol Ther;
11(2): 443-455, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38416391
9.
Residual Disease Activity in Canadian Patients With Psoriatic Arthritis Treated With Advanced Therapies: Results From a Multiregistry Analysis (UNISON-PsA).
J Rheumatol;
51(5): 479-487, 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38359937
10.
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL.
RMD Open;
10(1)2024 Feb 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38388171
11.
Circulating neutrophil extracellular trap remnants as a biomarker to predict outcomes in lupus nephritis.
Lupus Sci Med;
11(1)2024 Jan 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38177067
12.
Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis.
RMD Open;
10(1)2024 Jan 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38296802
13.
Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis.
Rheumatology (Oxford);
2024 Jan 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38218744
14.
Derivation and Internal Validation of a Disease-Specific Cardiovascular Risk Prediction Model for Patients With Psoriatic Arthritis and Psoriasis.
Arthritis Rheumatol;
76(2): 238-246, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37691498
15.
Patient clusters identified by machine learning from a pooled analysis of the clinical development programme of secukinumab in psoriatic arthritis, ankylosing spondylitis and psoriatic arthritis with axial manifestations.
Clin Exp Rheumatol;
42(3): 696-701, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38019168
16.
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.
Ann Rheum Dis;
83(1): 15-29, 2024 Jan 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37827694
17.
Different Immunologic Profiles Are Associated With Distinct Clinical Phenotypes in Longitudinally Observed Patients With Systemic Lupus Erythematosus.
Arthritis Rheumatol;
2023 Dec 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38073017
18.
Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study.
Rheumatol Ther;
10(6): 1637-1653, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37819505
19.
Incidence and predictors of demyelinating disease in spondyloarthritis: data from a longitudinal cohort study.
Rheumatology (Oxford);
2023 Oct 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37792508
20.
Psoriatic Arthritis and COVID-19: Patient Perspectives in a Large Psoriatic Arthritis Cohort.
J Rheumatol;
2023 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37657794